{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T21:28:10Z","timestamp":1781386090071,"version":"3.54.1"},"reference-count":10,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,21]]},"DOI":"10.1182\/blood.2025029930","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T15:31:05Z","timestamp":1755790265000},"page":"899-900","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Cracking the POD24 code in follicular lymphoma"],"prefix":"10.1182","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9635-5487","authenticated-orcid":false,"given":"Florian","family":"Scherer","sequence":"first","affiliation":[{"name":"University of Freiburg Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2025082111310434500_bib1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1182\/blood.2024027727","article-title":"Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment","volume":"146","author":"Claudel","year":"2025","journal-title":"Blood"},{"issue":"23","key":"2025082111310434500_bib2","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"2025082111310434500_bib3","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/bloodadvances.2022007949","article-title":"Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy","volume":"7","author":"Rodr\u00edguez-Sevilla","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"2025082111310434500_bib4","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","article-title":"Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy","volume":"128","author":"Jurinovic","year":"2016","journal-title":"Blood"},{"issue":"1","key":"2025082111310434500_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2017-11-816405","article-title":"A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy","volume":"132","author":"Bachy","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2025082111310434500_bib6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.annonc.2023.10.121","article-title":"Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial","volume":"35","author":"Cottereau","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"2025082111310434500_bib7","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"2025082111310434500_bib8","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2025082111310434500_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1470-2045(21)00591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"issue":"9","key":"2025082111310434500_bib10","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1200\/JCO.18.01907","article-title":"Reply to J. Wang et al","volume":"37","author":"Kurtz","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/8\/899\/2407082\/blood_bld-2025-029930-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/146\/8\/899\/2407082\/blood_bld-2025-029930-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T15:31:07Z","timestamp":1755790267000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/146\/8\/899\/546645\/Cracking-the-POD24-code-in-follicular-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025029930","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,21]]},"published":{"date-parts":[[2025,8,21]]}}}